Shots:

• Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then Alligator will be further eligible to receive $548.41M as development- approval- and sales milestone for all three product candidates along with royalties
• The focus of the collaboration is to discover three novel bispecific Abs directed towards immuno-oncology targets- selected by Orion
• Following the collaboration- Alligator will use its phage display libraries and RUBY bispecific platform to develop immuno-oncology product candidates

  | Ref: Alligator Bioscience | Image: Alligator Bioscience